OPR - Delayed Quote USD

SGMO Jul 2021 15.000 call (SGMO210716C00015000)

0.0500 0.0000 (0.00%)
At close: July 1 at 3:46 PM EDT
Key Events
Advanced Chart
Loading Chart for SGMO210716C00015000
DELL
  • Previous Close 0.0500
  • Open 0.0900
  • Bid 0.0000
  • Ask 0.0500
  • Strike 15.00
  • Expire Date 2021-07-16
  • Day's Range 0.0500 - 0.1000
  • Contract Range --
  • Volume 57
  • Open Interest 200

Recent News: SGMO

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Business Wire 4 days ago
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today

What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
Simply Wall St. last month
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Business Wire last month
Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations

Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations
Simply Wall St. last month

Q4 2023 Sangamo Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents last month
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Business Wire last month
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Business Wire last month
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Business Wire last month
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Business Wire 2 months ago
With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners

With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners
Simply Wall St. 2 months ago
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
Business Wire 2 months ago
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Simply Wall St. 5 months ago
View More